For Pfizer, Bigger as One May Be Better Than Smaller With Two


By deciding not to split in two after a lengthy evaluation, the New York-based drugmaker is keeping greater leverage with the health insurers and pharmacy benefit managers that have gained increasing power since it first considered a breakup years ago. Had it broken up, Pfizer would have turned into one company with older and generic products, and another with newer products.



from Biotech News